Safety of Recombinant Activated Factor VII in Randomized Clinical Trials

2010673 citationsJournal Articlebronze Open Access

Authors

Henning Friis Andersen · Novo Nordisk (Denmark)

Abstract

In a large and comprehensive cohort of persons in placebo-controlled trials of rFVIIa, treatment with high doses of rFVIIa on an off-label basis significantly increased the risk of arterial but not venous thromboembolic events, especially among the elderly. (Funded by Novo Nordisk.).

Topics & Keywords

Hemophilia Treatment and Research Blood Coagulation and Thrombosis Mechanisms Blood properties and coagulation

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: New England Journal of Medicine

Volume 363, Issue 19, pp. 1791-1800

DOI: 10.1056/nejmoa1006221

Field-Weighted Citation Impact: 41.86